Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, researchers are using the same tactics to advance prostate cancer treatment.

“A Gleason score of 9.” Veterans of prostate cancer will know those five words pack a punch. It is a grade-high diagnosis, meaning not only that cancer cells are aggressive but that they can spread ...

A Gleason reading of 9 one of the most virulent forms of prostate cancer is now fueling ex-President Joe Biden’s treatment effort. Biden, 82, is receiving radiation and hormone therapy, a treatment ...

New findings highlight Telomir-1’s impact on CASP8 and GSTP1, two critical genes that regulate cell death and glutathione-based detoxification pathways often disrupted in cancer. MIAMI, FLORIDA / ...

Findings complement previously announced results in triple-negative breast cancer (TNBC) and prostate cancer models, highlighting Telomir-1’s consistent impact on cancer cell survival pathways. MIAMI, ...

Findings expand Telomir-1's oncology profile into cancers of the blood, adding to previously reported activity in triple-negative breast, pancreatic, and aggressive prostate cancer models. MIAMI, FL / ...

MIAMI, FLORIDA / ACCESS Newswire / October 23, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) (“Telomir” or the “Company”), a pre-clinical biotechnology company developing therapies that target ...